Canadian Migraine sufferers have a new treatment option | Tech Reddy
[ad_1] – UBRELVI® The first and only oral CGRP receptor antagonist (hepant) approved by Health Canada for the acute treatment of migraine — UBRELVI® It has been shown to reduce or eliminate migraine attacks with a single oral tablet, with the flexibility to take an additional second dose for persistent pain. MONTREAL, November 16, 2022 … Read more